NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today the CE marking of Next Generation SedLine ® brain function monitoring for pediatric patients (1-18 years of age). With ...
Masimo Corporation MASI recently received the FDA’s clearance for SedLine brain function monitoring for pediatric patients (1-17 years of age) and the SedLine Pediatric EEG (electroencephalogram) ...
Masimo has made a name for itself as a prolific purveyor of noninvasive patient monitoring technologies, from the SET pulse oximeter to the recently CE-marked Rainbow SuperSensor, which continuously ...
Masimo Corporation MASI recently announced the findings of a prospective study published in Frontiers in Neurology. The study evaluated whether general anesthesia guided by Masimo SedLine Brain ...
Irvine-based Masimo Corp., which makes patient monitoring devices, said a study found one of its products effectively monitored babies and toddlers undergoing surgeries. Researchers wanted to measure ...
Masimo Corporation MASI recently announced the findings of a favorable study result wherein researchers evaluated the relationship between parameters derived from electroencephalogram (EEG) spectra ...
Irvine, CA-based Masimo (NASDAQ: MASI) has agreed to buy SEDLine, a manufacturer of brain function monitoring devices. The acquisition marks Masimo's commercial entry into the brain function ...
Four months after debuting W1 health watch at Arab Health 2022, Masimo Corp. reported a limited release of the consumer version of the device in the U.S. to 10,000 users on a first come-first served ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback